<DOC>
	<DOCNO>NCT01137526</DOCNO>
	<brief_summary>The purpose study test investigational medication , ABT-384 , safe effective treatment adult mild-to-moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>Efficacy Safety Study ABT-384 Subjects With Mild-to-Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>This Phase 2 study design evaluate safety efficacy ABT-384 approximately 260 adult mild-to-moderate Alzheimer 's Disease ( AD ) . Subjects randomized one four treatment group ( ABT-384 , donepezil , placebo ) 12-week Treatment Period .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . The subject caregiver must voluntarily sign date inform consent . If subject fully competent , full informed consent must obtain legal representative assent must obtain subject . 2 . Subject male female age 55 90 year age , inclusive , Day1 . 3 . Subject meet NINCDS/ADRDA criterion probable AD . 4 . Subject MiniMental Status Examination ( MMSE ) score 10 24 , inclusive , Screening Visit 1 . 5 . Subject Cornell Scale Depression Dementia ( CSDD ) score â‰¤ 10 Screening Visit 1 . 6 . With exception diagnosis mildtomoderate AD presence stable medical condition , subject generally good health base medical history , physical examination , vital sign , clinical lab test 12lead ECG . 7 . If female , subject must postmenopausal least 2 year surgically sterile . 8 . If male , subject surgically sterile ( vasectomy ) , sexually inactive , use barrier method birth control . 9 . Subject identify reliable , caregiver ( e.g. , family member , social worker , nurse ) , provide support ensure compliance study medication procedure . 10 . Subject caregiver fluent language use administration rating scale cognitive test sufficient visual , hear graphomotor skill complete procedure . 1 . Subject know hypersensitivity intolerance donepezil lead discontinuation know report history donepezil treatment failure . 2 . Subject currently take take medication treatment AD dementia within 60 day Screening Visit 1 , participate cognitive therapy treatment AD dementia . 3 . Subject history drug alcohol disorder ( abuse/dependence ) , base either DSMIVTR ICD10 criterion , exclude nicotine , within 2 year prior Screening Visit 1 . 4 . In opinion investigator , subject clinically significant uncontrolled medical psychiatric illness would affect safety subject . 5 . The subject current thyroid disease history thyroid disease , currently treat stable dose thyroid replacement medication . 6 . For reason investigator considers subject unsuitable candidate receive ABT384 donepezil .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>